Novo Nordisk has significantly decreased the monthly price of its diabetes drug Ozempic from approximately $1,000 to $499 for cash-paying U.S. patients. This price cut benefits self-paying patients, including those without insurance coverage. Over 70,000 U.S. pharmacies are involved through partnerships with GoodRx and NovoCare. The rationale behind this reduction emphasizes improving access to FDA-approved treatments while countering market pressures. Novo Nordisk prioritizes patient safety by discouraging the use of unsafe alternatives, reaffirming its commitment to making essential medications more affordable and accessible.
Novo Nordisk has announced a sweeping reduction in the cost of Ozempic for cash-paying U.S. patients with type 2 diabetes from nearly $1,000 to $499 per month.
The reduced price applies to self-paying patients and is available through partnerships with GoodRx and NovoCare, covering over 70,000 U.S. pharmacies.
Novo Nordisk stated that improving access to authentic, FDA-approved treatments is central to its mission, highlighting the importance of affordability and patient safety.
The decision follows growing calls for greater drug affordability and aims to prioritize patient safety, especially against the backdrop of competitive pressures in the market.
Collection
[
|
...
]